Patents by Inventor Gerardus Joseph Andreas Ariaans

Gerardus Joseph Andreas Ariaans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Site-specific conjugation of linker drugs to antibodies and resulting ADCs
    Patent number: 12180552
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Grant
    Filed: August 23, 2021
    Date of Patent: December 31, 2024
    Assignee: Byondis B.V.
    Inventors: Gerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans
  • Anti-5T4 antibodies and antibody-drug conjugates
    Patent number: 11584801
    Abstract: The present invention relates to antibodies against the human 5T4 oncofoetal antigen and corresponding antibody-drug conjugates that are suitable for testing in clinical trials. The antibodies are cross-reactive for humans and cynomolgus monkeys and exhibit an affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4 antigen. The invention further relates to the use of the antibodies and corresponding ADCs in the treatment of solid tumours and haematological malignancies.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: February 21, 2023
    Assignee: Byondis B.V.
    Inventors: Miranda Maria Cornelia Van Der Lee, Gerardus Joseph Andreas Ariaans, Jan Schouten, Marion Blomenrohr, Patrick Gerhard Groothuis, Rudy Gerardus Elisabeth Coumans
  • SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS
    Publication number: 20210388115
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Application
    Filed: August 23, 2021
    Publication date: December 16, 2021
    Inventors: Gerardus Joseph Andreas ARIAANS, Rudy Gerardus Elisabeth COUMANS
  • ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20210317231
    Abstract: The present invention relates to antibodies against the human 5T4 oncofoetal antigen and corresponding antibody-drug conjugates that are suitable for testing in clinical trials. The antibodies are cross-reactive for humans and cynomolgus monkeys and exhibit an affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4 antigen. The invention further relates to the use of the antibodies and corresponding ADCs in the treatment of solid tumours and haematological malignancies.
    Type: Application
    Filed: April 13, 2021
    Publication date: October 14, 2021
    Inventors: Miranda Maria Cornelia VAN DER LEE, Gerardus Joseph Andreas ARIAANS, Jan SCHOUTEN, Marion BLOMENROHR, Patrick Gerhard GROOTHUIS, Rudy Gerardus Elisabeth COUMANS
  • Site-specific conjugation of linker drugs to antibodies and resulting ADCS
    Patent number: 11136633
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: October 5, 2021
    Assignee: Byondis B.V.
    Inventors: Gerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans
  • Site-specific conjugation of linker drugs to antibodies and resulting ADCS
    Patent number: 11104968
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: August 31, 2021
    Assignee: Byondis B.V.
    Inventors: Gerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans
  • Anti-5T4 antibodies and antibody-drug conjugates
    Patent number: 11008400
    Abstract: The present disclosure relates to CDR defined antibodies targeting the 5T4 oncofoetal antigen (TPBG, 5T4, Wnt Activated Inhibitory Factor 1, WAIF1) which exhibit a binding affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4. Antibody-drug conjugates (ADCs), and their use in the treatment of human solid tumours and haematological malignancies are claimed.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: May 18, 2021
    Assignee: Byondis B.V.
    Inventors: Miranda Maria Cornelia Van der Lee, Gerardus Joseph Andreas Ariaans, Jan Schouten, Marion Blomenrohr, Patrick Gerhard Groothuis, Rudy Gerardus Elisabeth Coumans
  • SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS
    Publication number: 20190368000
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 5, 2019
    Inventors: Gerardus Joseph Andreas ARIAANS, Rudy Gerardus Elisabeth COUMANS
  • SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS
    Publication number: 20190367999
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 5, 2019
    Inventors: Gerardus Joseph Andreas ARIAANS, Rudy Gerardus Elisabeth COUMANS
  • Site-specific conjugation of linker drugs to antibodies and resulting ADCs
    Patent number: 10407743
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumors and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: September 10, 2019
    Assignee: Synthon Biopharmaceuticals B.V.
    Inventors: Gerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans
  • ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20190194346
    Abstract: The present disclosure relates to CDR defined antibodies targeting the 5T4 oncofoetal antigen (TPBG, 5T4, Wnt Activated Inhibitory Factor 1, WAIF1) which exhibit a binding affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4. Antibody-drug conjugates (ADCs), and their use in the treatment of human solid tumours and haematological malignancies are claimed.
    Type: Application
    Filed: November 24, 2016
    Publication date: June 27, 2019
    Inventors: Miranda Maria Cornelia VAN DER LEE, Gerardus Joseph Andreas ARIAANS, Jan SCHOUTEN, Marion BLOMENROHR, Patrick Gerhard GROOTHUIS, Rudy Gerardus Elisabeth COUMANS
  • SITE-SPECIFIC CONJUGATION OF LINKER DRUGS TO ANTIBODIES AND RESULTING ADCS
    Publication number: 20170080103
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.
    Type: Application
    Filed: May 22, 2015
    Publication date: March 23, 2017
    Applicant: SYNTHON BIOPHARMACEUTICAL B.V.
    Inventors: Gerardus Joseph Andreas ARIAANS, Rudy Gerardus Elisabeth COUMANS
  • Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
    Patent number: 9580501
    Abstract: A monoclonal secretory IgA antibody, which binds to and neutralizes human TNF?. The secretory antibody is useful in treating a variety of inflammatory conditions in humans.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: February 28, 2017
    Assignee: Synthon Biopharmaceuticals B.V.
    Inventors: Gerardus Joseph Andreas Ariaans, Frans van Dalen, Declan Thomas Nolan
  • Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases
    Patent number: 9573996
    Abstract: A monoclonal secretory IgA antibody, which binds to and neutralizes a human proinflammatory cytokine or which binds to and blocks a human proinflammatory cytokine receptor. The secretory IgA antibody is useful in treating a variety of inflammatory diseases in humans.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: February 21, 2017
    Assignee: Synthon Biopharmaceuticals B.V.
    Inventors: Gerardus Joseph Andreas Ariaans, Frans van Dalen, Declan Thomas Nolan
  • COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY DISEASES
    Publication number: 20150166649
    Abstract: A monoclonal secretory IgA antibody, which binds to and neutralizes a human proinflammatory cytokine or which binds to and blocks a human proinflammatory cytokine receptor. The secretory IgA antibody is useful in treating a variety of inflammatory diseases in humans.
    Type: Application
    Filed: December 14, 2012
    Publication date: June 18, 2015
    Inventors: Gerardus Joseph Andreas Ariaans, Frans van Dalen, Declan Thomas Nolan
  • COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY DISEASES
    Publication number: 20150010544
    Abstract: A monoclonal secretory IgA antibody, which binds to and neutralizes human p40 (the p40 subunit of IL-12 and IL-23). The secretory antibody is useful in treating a variety of inflammatory conditions in humans.
    Type: Application
    Filed: December 14, 2012
    Publication date: January 8, 2015
    Inventors: Gerardus Joseph Andreas Ariaans, Frans van Dalen, Declan Thomas Nolan
  • COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY DISEASES
    Publication number: 20140356357
    Abstract: A monoclonal secretory IgA antibody, which binds to and neutralizes human TNF?. The secretory antibody is useful in treating a variety of inflammatory conditions in humans.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 4, 2014
    Inventors: Gerardus Joseph Andreas Ariaans, Frans van Dalen, Declan Thomas Nolan
  • EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
    Publication number: 20140359902
    Abstract: Secretory IgA antibodies can be made by expression in a stably-transformed duckweed.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 4, 2014
    Inventors: Gerardus Joseph Andreas Ariaans, Frans van Dalen, Guy De Roo, Declan Thomas Nolan, Jeff Regan